Elevance Health, Inc. $ELV Shares Purchased by 8 Knots Management LLC

Key Points

• 8 Knots Management LLC increased its Elevance Health stake by 187.5% in the fourth quarter, buying an additional 333,635 shares to bring its total to 511,585 shares. The position was valued at about $179.3 million and made up 20.7% of the fund’s portfolio.
• Elevance Health’s latest quarterly results beat expectations, with EPS of $12.58 versus the $10.74 consensus and revenue of $49.49 billion, slightly above estimates. The company also maintained FY 2026 guidance of 19.850 EPS.
• Wall Street remains broadly positive on the stock, with 14 Buy ratings and a consensus “Moderate Buy” target price of $416.11. Elevance also announced a quarterly dividend of $1.72 per share, payable June 25, for an annualized yield of 1.7%.

8 Knots Management LLC lifted its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 187.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 511,585 shares of the company's stock after purchasing an additional 333,635 shares during the quarter. Elevance Health makes up 20.7% of 8 Knots Management LLC's investment portfolio, making the stock its 3rd biggest holding. 8 Knots Management LLC owned about 0.23% of Elevance Health worth $179,336,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Rossby Financial LCC lifted its position in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company's stock worth $28,000 after acquiring an additional 44 shares during the period. J.Safra Asset Management Corp acquired a new stake in Elevance Health during the 4th quarter worth approximately $32,000. ORG Partners LLC lifted its position in Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company's stock worth $38,000 after acquiring an additional 59 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Elevance Health during the 4th quarter worth approximately $38,000. Finally, Dorato Capital Management acquired a new stake in shares of Elevance Health in the 4th quarter valued at approximately $41,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the firm's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director owned 10,734 shares in the company, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ELV has been the subject of several recent analyst reports. Barclays raised their price target on Elevance Health from $408.00 to $480.00 and gave the company an "overweight" rating in a report on Tuesday, May 26th. Citigroup raised Elevance Health to a "buy" rating in a report on Wednesday, April 29th. Jefferies Financial Group reduced their price target on Elevance Health from $395.00 to $391.00 and set a "buy" rating for the company in a report on Monday, April 20th. Robert W. Baird raised their price objective on Elevance Health from $317.00 to $331.00 and gave the company a "neutral" rating in a research note on Thursday, April 23rd. Finally, Sanford C. Bernstein raised their price objective on Elevance Health from $384.00 to $424.00 and gave the company an "outperform" rating in a research note on Friday, April 24th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $416.11.

Elevance Health Stock Performance

Elevance Health stock opened at $403.74 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The stock has a fifty day moving average of $366.62 and a two-hundred day moving average of $344.86. The company has a market capitalization of $87.68 billion, a price-to-earnings ratio of 17.17, a PEG ratio of 2.29 and a beta of 0.67. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $426.98.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. During the same quarter last year, the business posted $11.97 earnings per share. Elevance Health's revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, analysts anticipate that Elevance Health, Inc. will post 26.93 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health's dividend payout ratio (DPR) is 29.26%.

Elevance Health Company Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.